XETRAPPH
Market cap87mUSD
Dec 23, Last price
10.10EUR
1D
0.00%
1Q
56.83%
IPO
-45.41%
Name
Apontis Pharma AG
Chart & Performance
P/E
—
P/S
2.28
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
37m
-33.67%
Net income
-11m
L
CFO
-13m
L
Profile
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company was founded in 1946 is headquartered in Monheim am Rhein, Germany.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 36,964 -33.67% | 55,727 8.87% | 51,184 30.44% | |||
Cost of revenue | 20,205 | 25,802 | 22,000 | |||
Unusual Expense (Income) | ||||||
NOPBT | 16,759 | 29,925 | 29,184 | |||
NOPBT Margin | 45.34% | 53.70% | 57.02% | |||
Operating Taxes | (3,543) | 1,139 | 994 | |||
Tax Rate | 3.81% | 3.40% | ||||
NOPAT | 20,301 | 28,785 | 28,191 | |||
Net income | (11,303) -520.38% | 2,689 | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (1,836) | 38,000 | ||||
BB yield | 2.63% | -22.35% | ||||
| Debt | ||||||
Debt current | 6,020 | |||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | 15,258 | 11,016 | 9,965 | |||
Net debt | (21,597) | (37,579) | (31,067) | |||
| Cash flow | ||||||
Cash from operating activities | (12,600) | 11,020 | 3,433 | |||
CAPEX | (3,263) | |||||
Cash from investing activities | (2,900) | |||||
Cash from financing activities | 6,000 | 20,121 | ||||
FCF | 16,910 | 33,758 | 17,826 | |||
| Balance | ||||||
Cash | 26,816 | 36,345 | 29,840 | |||
Long term investments | 801 | 1,234 | 1,227 | |||
Excess cash | 25,769 | 34,792 | 28,508 | |||
Stockholders' equity | 8,500 | 8,500 | 8,500 | |||
Invested Capital | 43,041 | 43,480 | 42,110 | |||
ROIC | 46.93% | 67.26% | 107.59% | |||
ROCE | 32.00% | 56.16% | 57.23% | |||
| EV | ||||||
Common stock shares outstanding | 8,500 | 8,500 | 8,500 | |||
Price | 4.75 -42.07% | 8.20 -59.00% | 20.00 | |||
Market cap | 40,375 -42.07% | 69,700 -59.00% | 170,000 | |||
EV | 18,778 | 32,121 | 138,933 | |||
EBITDA | 18,643 | 29,926 | 30,931 | |||
EV/EBITDA | 1.01 | 1.07 | 4.49 | |||
Interest | 71 | 48 | 406 | |||
Interest/NOPBT | 0.42% | 0.16% | 1.39% | |||